Lexeo
Lexeo Therapeutics Unveils Promising Interim Data for LX1001 Gene Therapy in APOE4-Associated Alzheimer’s Disease
Lexeo Therapeutics, LX1001, Gene Therapy, Alzheimer’s Disease, APOE4, APOE2, Clinical Trial, Phase 1/2
Lexeo Therapeutics Reports Promising Early Data for Gene Therapy LX2006 in Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics, LX2006, Gene Therapy, Friedreich Ataxia, Cardiomyopathy, Clinical Trials, Rare Genetic Disorders